← Browse by Condition
Medical Condition

hepatocellular carcinoma hcc

Total Trials
21
Recruiting Now
21
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for hepatocellular carcinoma hcc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hepatocellular carcinoma hcc Clinical Trials

How many clinical trials are currently recruiting for hepatocellular carcinoma hcc?
ClinicalMetric currently tracks 21 actively recruiting clinical trials for hepatocellular carcinoma hcc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 21. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hepatocellular carcinoma hcc?
hepatocellular carcinoma hcc research spans Phase 1 (5 trials), Phase 2 (6 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hepatocellular carcinoma hcc clinical trial?
Eligibility criteria for hepatocellular carcinoma hcc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
5
Phase 2
6
Phase 3
1
Top Sponsors
Seoul National University Hospital 3 trials
Imperial College London 1 trial
Charite University, Berlin, Germany 1 trial
Nanjing Tianyinshan Hospital 1 trial
Second Affiliated Hospital, Zhejiang University, School of Medicine 1 trial

Recruiting Clinical Trials

NCT07714538
Recruiting
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
Enrollment
1,000 pts
Location
United Kingdom
Sponsor
Imperial College London
View Trial →
NCT06821958
Recruiting
Amplitude-modulated Radiofrequency Electromagnetic Field Treatment for Advanced Hepatocellular Carcinoma (Immune-RF)
Enrollment
36 pts
Location
Germany
Sponsor
Charite University, Berlin, Ge...
View Trial →
NCT06893887
Recruiting
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Enrollment
300 pts
Location
China
Sponsor
Nanjing Tianyinshan Hospital
View Trial →
NCT07422753 Phase 2
Recruiting
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Enrollment
36 pts
Location
China
Sponsor
Second Affiliated Hospital, Zh...
View Trial →
NCT07226869
Recruiting
Computer Guided Microwave Liver Ablation
Enrollment
84 pts
Location
United States
Sponsor
NE Scientific INC
View Trial →
NCT06773845 Phase 2
Recruiting
Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria
Enrollment
100 pts
Location
South Korea
Sponsor
Seoul National University Hosp...
View Trial →
NCT07689175 Phase 2
Recruiting
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Enrollment
60 pts
Location
United States
Sponsor
University of Texas Southweste...
View Trial →
NCT06841172 Phase 3
Recruiting
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Enrollment
132 pts
Location
China
Sponsor
Shandong Cancer Hospital and I...
View Trial →
NCT06979219
Recruiting
Streamlining Radioembolization for Small HCC
Enrollment
146 pts
Location
South Korea
Sponsor
Seoul National University Hosp...
View Trial →
NCT06860490 Phase 2
Recruiting
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Enrollment
164 pts
Location
China
Sponsor
Fudan University
View Trial →
NCT06999174
Recruiting
Multiparametric MRI for Characterization of Hepatocellular Carcinoma
Enrollment
128 pts
Location
Germany
Sponsor
University Hospital Muenster
View Trial →
NCT06653062
Recruiting
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
Enrollment
50 pts
Location
China
Sponsor
Tongji Hospital
View Trial →
NCT06726161 Phase 1, Phase 2
Recruiting
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Enrollment
590 pts
Location
United States
Sponsor
RayzeBio, Inc.
View Trial →
NCT07782632
Recruiting
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
Enrollment
467 pts
Location
China
Sponsor
Anhui Provincial Hospital
View Trial →
NCT07594964 Phase 1
Recruiting
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
Enrollment
48 pts
Location
China
Sponsor
Shenzhen Xinhe Biomedical
View Trial →
NCT07381634 Phase 2
Recruiting
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
Enrollment
134 pts
Location
China
Sponsor
First Affiliated Hospital of W...
View Trial →
NCT07419841 Phase 1
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Enrollment
70 pts
Location
United States
Sponsor
Compass Therapeutics
View Trial →
NCT07476651
Recruiting
Scout Dose of Resin Microspheres
Enrollment
30 pts
Location
South Korea
Sponsor
Seoul National University Hosp...
View Trial →
NCT07176650 Phase 1
Recruiting
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Enrollment
246 pts
Location
United States, China
Sponsor
Shanghai Henlius Biotech
View Trial →
NCT07178587
Recruiting
Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors
Enrollment
28 pts
Location
France
Sponsor
Nantes University Hospital
View Trial →
NCT07369505 Phase 1
Recruiting
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Enrollment
27 pts
Location
Australia
Sponsor
SAPU NANO (US) LLC
View Trial →

Related Conditions

pancreatic ductal adenocarcinoma pdac (2) radioembolization (2) renal cell carcinoma rcc (2) oesophageal squamous cell carcinoma (1) oesophageal adenocarcinoma (1) gastric adenocarcinoma (1) cholangiocarcinoma (1) colorectal adenocarcinoma (1) oligoprogressive metastatic disease (1) radiotherapy (1) systemic therapy (1) biliary cancer cholangiocarcinoma gall bladder cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology